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Abstract
Social media is fundamentally altering how we access health information and make decisions about medical
treatment, including for terminally ill patients. This specifically includes the growing phenomenon of patients who
use online petitions and social media campaigns in an attempt to gain access to experimental drugs through
expanded access pathways. Importantly, controversy surrounding expanded access and “compassionate use”
involves several disparate stakeholders, including patients, manufacturers, policymakers, and regulatory agencies—all
with competing interests and priorities, leading to confusion, frustration, and ultimately advocacy. In order to explore
this issue in detail, this correspondence article first conducts a literature review to describe how the expanded access
policy and regulatory environment in the United States has evolved over time and how it currently impacts access to
experimental drugs. We then conducted structured web searches to identify patient use of online petitions and social
media campaigns aimed at compelling access to experimental drugs. This was carried out in order to characterize the
types of communication strategies utilized, the diseases and drugs subject to expanded access petitions, and the
prevalent themes associated with this form of “digital” patient advocacy. We find that patients and their families
experience mixed results, but still gravitate towards the use of online campaigns out of desperation, lack of
reliable information about treatment access options, and in direct response to limitations of the current fragmented
structure of expanded access regulation and policy currently in place. In response, we discuss potential policy reforms
to improve expanded access processes, including advocating greater transparency for expanded access programs,
exploring use of targeted economic incentives for manufacturers, and developing systems to facilitate patient
information about existing treatment options. This includes leveraging recent legislative attention to reform
expanded access through the CURE Act Provisions contained in the proposed U.S. 21st Century Cures Act.
While expanded access may not be the best option for the majority of individuals, terminally ill patients and
their families nevertheless deserve better processes, policies, and availability to potentially life-changing
information, before they decide to pursue an online campaign in the desperate hope of gaining access to
experimental drugs.
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Background
The widespread use of social media is changing the way
that individuals and social networks interact and how
they share, process, and consume health information, in-
cluding about terminal illnesses [1]. Yet, as social media
platforms increasingly become ubiquitous, many un-
answered questions remain, regarding the impact of
this technology on individual and population-based health
through changes in health behavior and information
seeking [2–7]. This includes the growing use of online
petitions and social media campaigns in an attempt to
gain access to experimental treatments [8–12]. This
form of patient-driven advocacy enabled by “digital
health” contrasts sharply with the traditional course of
drug development and expanded access policies (also
known as compassionate use) currently utilized by the
industry and the U.S. Food and Drug Administration
(FDA) [10, 13]. It also represents a direct response to
the limitations of the current regulatory pathway and
expanded access policies by patients who are desperate
and have no viable treatment alternatives [14].
The phenomenon also raises several ethical and practical
questions regarding how to ensure equitable distribution
and access to scarce resources (i.e. the drug candidate), the
possibility of potential harm/safety issues from untested
treatment, and concerns that premature access could com-
promise the routine drug approval process [8–10, 15–18].
In exploring this controversial topic, we first describe the
current regulatory framework for expanded access in the
United States, discuss recent trends in state “right-to-try”
legislation, and then identify and characterize case studies
of expanded access online petitions and social media cam-
paigns used by patients and their families. We conclude
with a discussion of potential policy reforms to improve
expanded access processes, including leveraging recent
legislative attention focusing on reforming expanded
access in the CURE Act Provisions contained in the
proposed U.S. 21st Century Cures Act.
Methods
Literature selection criteria and online search strategy
In order to explore the U.S. policy environment for ex-
panded access, we first searched PubMed (Medline)
database for English language articles published between
2005 and 2015, which contained the keywords “expanded
access”, “expanded access programs”, “compassionate use”,
“right-to-try”, and “experimental drugs” in the title/abstract
field using the advanced search function. We excluded
literature reporting results, reviews, or meta-analyses of
expanded access clinical studies or case reports, evalua-
tions of expanded access programs, economic analysis of
expanded access treatments, discussion about expanded
access in countries outside of the United States, expanded
access for non-pharmaceutical products (e.g. stem cell
treatments and medical marijuana), and other literature
that did not have policy relevance to the topic. The goal of
this literature review was to describe the evolution and
current regulatory and policy framework for expanded
access in the United States.
We supplemented information from PubMed with
additional sources of information by searching for keywords
on Google search engine. This information included
grey literature (informally published and non-peer
reviewed written material), technical reports/guidance
from government agencies, news reports, information
from non-governmental organizations/patient advocacy
groups, pending and enacted U.S. legislation on the topic,
searching government databases relevant to expanded
access data, and reviewing information from the FDA’s
website. These additional information sources provided
more up-to-date and current information on expanded
access developments, policy issues, and debate, and
helped to identify a preliminary set of expanded access
patient case studies (as identified and reviewed below).
Further, in order to identify and characterize patient
use of online petitions and social media and its possible
association with expanded access treatment and policy,
we also conducted structured web search queries. The
keywords utilized in the literature review were also used
to conduct searches directly on popular online petition
sites and social media platforms in order to identify indi-
vidual patient expanded access campaign case studies. We
then reviewed identified case studies (limited to U.S. pa-
tients or their families) who sought expanded access to ex-
perimental treatment and coded content for information
on types of platforms used, use of multimedia, number of
signatures obtained (for campaigns using online petitions),
category of disease addressed, type of treatment requested,
and name of company/organization petitioned.
The literature review and structured Internet search
query was conducted from December 2014–2015. A visual
description of the overall study methodology is provided
in Fig. 1.
Findings
Expanded access regulatory framework
The debate regarding expanded access is not novel to
social media, with regulations first issued by the FDA in
the late 1980s during the height of the HIV/AIDS epidemic
and more recently becoming a topic of debate in the 2014
Ebola outbreak in West Africa [10, 19–24]. A critical turn-
ing point for patient advocacy related to expanded access
occurred in 2001, when Abigail Burroughs, a terminally ill
21-year-old head and neck cancer patient, mounted a
highly publicized campaign in an attempt to gain access to
the then experimental epidermal growth factor receptor
(EGFR) inhibitor drug Erbitux (INN: cetuximab) [25–27].
Her subsequent death in June 2001 led to the formation of
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the “Abigail Alliance”, an organization whose mission is to
help create wider access to developmental cancer drugs
and drugs for other serious life-threatening diseases, and
whose efforts have led to congressional hearings, litigation
against the FDA, and ultimately a landmark 2008 decision
by the U.S. Court of Appeals for the District of Columbia
ruling that patients did not have the constitutional right to
access experimental drugs [18, 22, 26–33]. Public awareness
and pressure from this event also led to a rapid growth
in expanded access programs (EAPs) created by drug
manufacturers, particularly for gene-targeted cancer
therapeutics [34].
In 2009, substantial revisions were made to FDA policies
to streamline the expanded access application process
used by providers and manufacturers on behalf of patients.
These revisions also included a reorganization of applica-
tion categories (individual, intermediate-size populations,
large populations) and sub-categories based on whether
an existing investigational new drug application (IND) is
available and/or whether it constitutes an emergency (de-
fined as a life-threatening situation) [10, 35–37]. The FDA
also released a 2013 draft guidance document clarifying
the implementation of its 2009 expanded access process
revisions and recent draft guidance in February 2015 to
substantially simplify forms and speed up the process for
submitting individual patient expanded access INDs
[22, 38–41]. Based on data from the FDA, numerous
applications are submitted each year, with the agency
receiving an average of 1,206 requests annually (based
on data from October 2009–September 2014) with an
overall approval rate of 99 % (Fig. 2) [42–44]. The vast
majority of these applications are for single-patient, non-
emergency (48 %) or emergency use (44 %) INDs (versus
intermediate-size patient population access programs with
Fig. 1 Study methodology
Mackey and Schoenfeld BMC Medicine  (2016) 14:17 Page 3 of 10
multiple patients with the same disease or condition seek-
ing access to the same drug), and are assessed by the FDA
on a case-by-case basis [8, 42].
Although the FDA may approve the vast majority of
applications that it receives, a critical challenge to patient
access continues to occur prior to FDA involvement as ap-
plicants must first obtain agreement/approval from the
manufacturer/IND holder [10, 19, 43]. This approval
process varies by sponsor and drug in question; many
large companies have established compassionate access/
EAP programs for particular drugs, but many small firms/
start-ups lack any process [45, 46]. This leaves patients
unable to obtain approval with few options other than
appealing directly to company officials. Though firms may
wish to provide an experimental drug for humanitarian,
public relations, or other internal reasons, they are under
no federal legal obligation to do so; indeed, courts have
consistently ruled that terminally ill patients have no
constitutional right to treatment with unapproved drugs
[10, 19, 32, 47]. Additionally, concerns regarding reporting
adverse events to the FDA arising from use in uncon-
trolled settings, limited drug availability, and the need to
fully commit sponsors’ resources to the clinical trial and
marketing approval process, may limit the willingness of
firms to allow expanded access [9, 10, 32, 35, 48].
Logistics for investigational drug availability are also
challenging, since these drugs are typically manufactured
in small lot sizes that can be impacted by manufacturing
complications and/or limited availability of active pharma-
ceutical ingredient/raw materials [10, 22, 32, 45, 49].
Equally challenging is the trepidation that providing
patient access through expanded access channels could
impact enrollment in controlled clinical trials [14, 15, 48,
50]. This is particularly the case for rare cancers or other
orphan diseases, where the number of eligible study
participants is limited [51–53]. Further, even if a sponsor
establishes an EAP, determining the appropriate process
to ensure equitable access if there is overwhelming
demand can lead to difficult decisions regarding who are
the best candidates to receive access and which requests to
deny [8]. As an example of a response to these challenges,
in May 2015, pharmaceutical manufacturer Johnson &
Johnson announced a partnership with the NYU School of
Medicine to establish an external advisory committee to
guide its decisions on compassionate use requests [54].
Legal and policy developments
In response to the perceived limitations of the FDA’s ex-
panded access regulatory structure, 21 U.S.A. states have
passed legislation designed to bypass the FDA’s authority
to regulate experimental drug access [55, 56]. The first
“right-to-try” law was passed in Colorado in May 2014,
allowing patients access to experimental drugs without
FDA approval and requiring only the drug sponsor’s per-
mission, with similar laws now enacted in several other
states [19, 57]. Arizona became the first state to pass a
measure by public vote in November 2014 for “right-to-
try” access and California is the most recent state to
consider passing such legislation [58]. Generally, these
various laws (mostly based on a model law drafted by
the Goldwater Institute in 2014) require that patients
give informed consent, have a terminal illness, have
considered all other FDA-approved treatment options,
have a prescription or recommendation from the pa-
tient’s physician for investigational treatment, and have
medical documentation that certain requirements have
been met [19, 57].
However, “right-to-try” laws have been widely criticized
and uncertainty remains as to whether they can survive
constitutional legal challenges [10, 19, 55]. Specifically,
prior court rulings and the Supremacy Clause of the U.S.
Constitution allows federal law to preempt conflicting
state laws rendering them unenforceable [19, 55]. Criti-
cism also focuses on the fact that these laws fail to address
fundamental access barriers experienced by patients:
primarily sponsors failing to provide compassionate use
Fig. 2 Summary of FDA Expanded Access Submission Reports (13 October 2009–30 September 2014). Source: data summarized from [42]
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approval. Under “right-to-try” laws, participation by
sponsors is voluntary, meaning that there remains no
legal obligation to approve patient access to experimental
drugs. The statutes may also contain rigorous informed
consent requirements, but not all legislation provides
adequate protection for sponsors and clinicians from
potential liability, as some do not allow decisive releases of
liability and others have no limitations on tort liability,
likely further disincentivizing participation [19, 55, 59].
The statutes also do not require insurers to cover the cost
of experimental treatments and fail to prohibit sponsors
or providers from charging patients any amount they des-
ignate for activities associated with the administration of
experimental treatments, potentially opening the door to
exorbitant or predatory pricing to an extremely vulnerable
patient population desperate for treatment [19, 55]. An-
other limitation to these laws is a general lack of system-
atic data collection and information sharing by clinicians
and patients regarding treatment outcomes, even if only
from an observational perspective. Due to these inherent
challenges and lingering questions about federal preemp-
tion, some commentators have recommended that state
“right-to-try” laws be struck down, in favor of a federal
legislative policy “fix” [19, 55].
Social media: an alternative access point?
Given the procedural and policy challenges of current
expanded access pathways for investigational drugs, bio-
logics, and medical devices, many terminally ill patients
have sought alternative means for accessing treatments
that are untested but may nevertheless present them
with their only, albeit uncertain, chance of a life-saving
intervention [8, 11, 60]. This desperate situation has given
rise to patient-driven advocacy attempting to compel ac-
cess to EAPs through the use of social media; a technology
with multiple channels of engagement and increasing in
the sphere of social and political influence [2, 6, 61].
Specifically, patients and their families use a variety of
online petitions, Facebook pages, Twitter accounts, You-
Tube videos, and other social media platforms to raise
awareness for their cause, prompt letter writing campaigns,
attract traditional media coverage, and otherwise exert pub-
lic pressure to obtain experimental drug access primarily
targeting drug manufacturers [11, 45]. For example,
compassionate use petitions facilitated by Change.org
(an online petition tool hosting campaigns for individuals/
organizations with over 100 million users in 196 coun-
tries) have increased from a total of three petitions in 2009
to 20 petitions in 2013 [62]. Interestingly, over the same
time period, citizen petitions submitted to the FDA
(searchable on the U.S. government website, www.regula-
tions.gov) requesting changes or creation of new approval
mechanisms for expanded access, have not experienced
similar increases, indicating that patients may be focused
more on engaging in advocacy via popularized online and
social media channels [47].
In order to better understand and characterize the
growing use of online petitions and social media, and its
potential impact on treatment access for terminally ill
patients, we conducted structured Internet search queries
to identify case studies involving U.S. patients or their
families who sought expanded access to experimental
treatments through online campaigns. Our review yielded
a total of 23 case studies, of which 87 % (n = 20) used an
online petition (78 % of these used Change.org). The
remaining three campaigns that did not use an online pe-
tition platform mobilized their expanded access campaign
primarily using social media. The gender distribution
among reviewed online campaigns was split with 52 %
(n = 12) female patients compared to 48 % (n = 11) male
patients and an age distribution of 61 % (n = 14) adults
versus 39 % (n = 9) children subject of a petition as identi-
fied through self-reported information on websites.
The community with the highest representation among
online expanded access campaigns was cancer patients
and their families, who comprised 83 % (n = 19) of all case
studies (which included seven pediatric cancer patients)
reviewed. Terminally ill patients who used online petitions
and social media suffered from a variety of cancer types,
including skin, kidney, breast, brain, lung, gastric, ovarian,
and soft tissue cancers. The specific cancers identified in
the case studies were: stage IV melanoma (n = 4); kidney
cancer (n = 2); breast cancer (n = 2); diffuse intrinsic pon-
tine glioma (DIPG) brainstem tumor (n = 2); and lung can-
cer, gastric cancer, brain tumor (suspected, but not proven
to be medulloblastoma), teratoma brain tumor, anaplastic
medulloblastoma, stage IIIC ovarian cancer, stage IV
alveolar soft part sarcoma, mantle cell lymphoma, and
immunosuppression treatment for malignant rhabdoid
tumor of the kidneys resulting in adenovirus (all with
one patient). It should be noted that certain patient
advocacy groups, such as the Multiple Myeloma Research
Foundation, have actively enabled direct access to EAPs
through partnerships with drug manufacturers. Hence,
patients suffering from these cancer types may be less
likely to pursue online campaigns given their ability to ac-
cess EAPs through existing advocacy channels. Other non-
cancer diseases that are extremely debilitating and life-
threatening were also subject to petitions/campaigns, in-
cluding spinal muscular atrophy (SMA), MPS II Hunter
syndrome, coxsackievirus, and amyotrophic lateral
sclerosis (ALS). Collectively these diseases comprised
17 % (n = 4) of all case studies identified.
Many of the case studies were focused on patients
attempting to gain access to the same experimental drug
class/therapeutic, although often for the treatment of
different cancer types. As an example, 35 % (n = 8) of ex-
panded access case studies reviewed were associated with
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the novel immunotherapy anti-PD-1 (a negative regulator
of T-cell function that appears to recruit a much stronger
immune response to tumor cells) [63]. Some of the drugs
petitioned in expanded access online campaigns have also
been subsequently approved by the FDA, including the
Merck & Co., Inc. anti-PD-1 drug pembrolizumab (trade
name Keytruda), which was approved for the treatment of
non-small cell lung cancer in 2014. While several of these
experimental drugs were approved for the specific indi-
cations subject to petitions (e.g. ramucirumab for advanced
gastric adenocarcinoma and pertuzumab for HER2-positive
metastatic breast cancer), others were approved for
other treatments, indicating that even after FDA market
authorization, expanded access patients may still lack
access to an approved “labeled” drug for their specific
condition. However, it is important to note that off-label
prescribing and use for the treatment of cancer is com-
mon, and while manufacturers cannot legally promote a
drug “off-label” (i.e. for indications not approved by the
FDA), physicians are free to prescribe a drug for any
clinical condition they see fit [52, 64, 65].
Although drug companies targeted by expanded access
campaigns/petitions as a group comprised of various large,
multinational global pharmaceutical firms and a few smaller
mid-sized and start-up firms, Bristol-Myers Squibb and
Merck & Co., Inc. were the target of the highest number of
petitions due to demand for anti-PD-1 (see Table 1). Three
patients also sought access to antineoplaston therapy, a
highly controversial alternative cancer treatment that can
be obtained in clinical trials and has also been approved by
the FDA through expanded access INDs [66]. Other experi-
mental treatments for diseases other than cancer included
a petition for NurOwn™ (a form of autologous adult stem
cell therapy for treatment of the neurodegenerative disease
amyotrophic lateral sclerosis).
The number of signatures obtained by online expanded
access petitions reviewed (i.e. an indication of outreach/
public engagement) varied widely from a high of 525,738
(patient with stage IV melanoma) to a low of 448 (patient
with lung cancer) [67]. Observed characteristics of
“successful” case studies (defined as those that garnered
greater than 100,000 signatures in online petitions) shared
similar communication and outreach strategies including:
1) use of an online petition combined with message
propagation through active engagement on Facebook
and Twitter; and 2) use of an additional communication
platform to better articulate the personal struggle of the
patient (e.g. through the use of a personal website, blog,
or YouTube video patient testimonial). In contrast,
campaigns that received fewer signatures (i.e. 20,000 or
less) often relied solely on the online petition site to
raise support or only engaged the public with one add-
itional communication medium (i.e. a blog or Facebook
page). Specifically, several of the high-profile case studies
reviewed which received significant traditional media
coverage, appeared to have a multimedia strategy in place
that was well-articulated, professionally executed (includ-
ing various multimedia assets), and included coordinated
message propagation across multiple popular online plat-
forms, such as Facebook, Twitter, YouTube videos, blog
Table 1 Sponsor drug manufacturers subject to expanded access campaigns/petitions
Name of sponsor Size of companya Publicly traded? (Yes/No) Number of requestsb
BioMarin Pharmaceutical Inc. Large Yes (NASDAQ Stock Market: BMRN) 1
Bayer AG Large Yes (Frankfurt Stock Exchange: BAYN) 1
Bristol-Meyers Squibb Large Yes (New York Stock Exchange: BMY) 5
Chimerix Inc. Small Yes (NASDAQ Stock Market: CMRX) 1
CureTech Ltd. Small No 1
Eli Lilly and Company Large Yes (New York Stock Exchange: LLY) 1
Genentech Inc. (wholly owned subsidiary of
F. Hoffmann-La Roche)
Large Yes (SIX Swiss Exchange: ROG; OTCQX: RHHBY) 4
ISIS Pharmaceuticals Inc. Small Yes (NASDAQ Stock Market: ISIS) 1
MedImmune, LLC (wholly owned subsidiary
of AstraZeneca)
Large Yes (London Stock Exchange, OMX, New York
Stock Exchange: AZN)
1
Merck & Co., Inc. Large Yes (New York Stock Exchange: MRK) 8
Pfizer Inc. Large Yes (New York Stock Exchange: PFE) 1
Pharmacyclics LLC Large Yes (NASDAQ Stock Market: PCYC) 1
Shire Plc Large Yes (London Stock Exchange: SHP; NASDAQ
Stock Market: SHPG)
1
Total number of firms: 13 Total number of requests: 27
aBusinesses classified as small (<500 employees) according to the U.S. Small Business Administration (under NAICS Association classification 541711, Research and
Development in Biotechnology); btotal number of requests equal more than the number of cases reviewed (23), because several patients requested access from
more than one sponsor
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sites, Tumblr, and CaringBridge.com (a social media pa-
tient support website) in addition to personal websites
(see Additional file 1: Table S1 for a summary of all
campaigns) [14, 68]. However, achieving robust public
engagement and media coverage did not appear to as-
sociate with better chances of accessing experimental
treatment through EAPs, as many of the “successful”
case studies reviewed self-reported not gaining access
to the treatment desired.
Despite variation in diseases addressed, treatment sought,
and sophistication of online communication strategies,
virtually all campaigns reviewed included content in their
patient testimonials and narratives reinforcing common
themes inherent to the struggle of terminally ill patients
seeking expanded access. Although a full qualitative con-
tent analysis of online campaign data is beyond the scope
of this article, the content generally grouped into themes
of: a) rapid deterioration of patient’s health indicating an
immediate and urgent need for experimental treatment;
b) lack of any alternative treatment options and/or
exhausting all available treatment options; c) descrip-
tion of the devastating impact of the condition on the
patient’s family in order to encourage public support; d)
identifying a drug manufacturer (and in some cases the
FDA) as the primary barrier for lack of access; and e)
overwhelmingly “positive” characterization of experimental
drugs petitioned (including characterizing an experimental
drug as a “wonderdrug”). Collectively, online campaigns ap-
peared to reinforce and propagate a common and shared
narrative among terminally ill patients seeking expanded
access: that no other treatment options are available; that
patients are being denied access to treatment; and experi-
mental drug access represents their last and best hope for a
life-saving intervention.
Limitations
This study has certain limitations that may impact the
validity and generalizability of results in relation to ex-
panded access online patient behavior. Specifically, the
results are limited by the sampling and search method-
ology used in the study, which relied on a combination
of keyword queries on a popular search engine and
using in-site searches directly on online petition and social
media platforms. These queries return non-random search
results prioritizing content based on the search engine or
website platform’s own propriety algorithm, which deter-
mines the relevance to the topic and may not be compre-
hensive. Website sampling was also limited to a specific
point in time and five related search terms. Additionally,
we did not pursue a formal in-depth coding or qualitative
analysis of content contained on online petitions and
social media sites to more appropriately identify themes
associated with the topic. Hence, these factors may affect
the generalizability of results and limits some of the
assumptions made by authors.
Discussion
This review of the expanded access digital environment
indicates that although there is a mix of drug candidates,
firms petitioned, social media strategies, and treatment
access outcomes, one particular trend stands out: the
majority of expanded access online petitions and social
media campaigns involve cancer patients and their families.
This may not be particularly surprising given that an esti-
mated 589,000 Americans are expected to die from cancer
in 2015, making it the second most common cause of death
in the country [69]. Additionally, the narratives included in
the vast majority of case studies examined indicate that
petitions and social media are used out of desperation,
as patients have exhausted conventional treatment op-
tions, including enrolling in manufacturer clinical trials.
Additionally, the regulatory and policy environment for
expanded access leaves much to be desired, as manu-
facturers continue to lack needed incentives to more
uniformly develop EAPs, patients are often unaware of
expanded access pathways or how to navigate them,
and “right-to-try” laws have their own inherent legal and
practical challenges.
From the patient advocacy perspective, a review of online
campaigns indicates a wide variation in levels of sophistica-
tion and engagement with equally inconsistent outcomes
for gaining access to treatment. Some campaigns appear to
be professionally prepared marketing presentations with at-
tractive visuals and articulately worded summaries outlin-
ing the arduous journeys of terminally-ill patients and
families. Others are less polished, containing only basic in-
formation describing the patient’s condition and lacking
sufficient detail as to what action the public can take to
help them access experimental drugs. What makes a
“successful” expanded access campaign ultimately re-
mains uncertain despite our review, given the small sam-
ple size of cases reviewed, unique circumstances of each
patient, and the uncertain outcome based on whether ac-
cess was actually achieved. However, campaigns observed
with the most Change.org signatures and/or social media
interaction/presence also appear to have garnered sub-
stantial media coverage from popular news outlets that
have helped further their cause (e.g. CNN, The Today
Show).
Given the high level of variability and uncertain bene-
fit of patient use of online petitions and social media,
combined with the challenges faced by the FDA, manu-
facturers, and state governments in improving expanded
access through regulation and public policy, stakeholders
should begin the process of exploring policy changes at
the federal level that can improve patient education and
facilitate more efficient exploration of available options
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for pursuing expanded access. Policy changes should focus
on developing transparent, equitable, and standardized pro-
cesses, which balance the competing needs of terminally ill
patients with the reality of commercial pressures, possibility
of poor drug-to-candidate fit, and scarce availability of
experimental drugs. Currently, terminally ill patients are
left to navigate a confusing patchwork of manufacturer
EAPs, recently enacted state “right-to-try” laws, FDA’s re-
vised expanded access pathway, and various information
sources online. This confusion regarding access options to
experimental drugs largely emanates from the fact that
manufacturers are not transparent about their expanded
access policies and their specific parameters for approving
requests.
In response, the proposed 2015 Andrea Sloan Com-
passionate Use Reform and Enhancement (CURE) Act
(H.R.909, 114th Congress), named after an ovarian cancer
patient who died in 2014, would have amended the Federal
Food, Drug, and Cosmetic Act to require companies to
publicly disclose corporate expanded access policies for
certain investigational drugs. The majority of the provisions
of the CURE Act were then incorporated into legislation
approved by the U.S. House of Representatives in July 2015
known as the 21st Century Cures Act (H.R.6, Title II,
Subtitle E), a highly touted piece of bipartisan legislation
aimed at modernizing and accelerating the discovery, de-
velopment, and delivery of life-saving drugs and therapy.
The incorporated legislation (collectively referred to as
“CURE Act Provisions”) would require companies to: 1)
establish a procedure and single point-of-contact for ex-
panded access requests; 2) explain the general criteria for
sponsor’s approval of such requests; and 3) disclose the
amount of time anticipated to respond to requests [70].
Conspicuously absent from the CURE Act Provisions was
a requirement in the original CURE Act requiring com-
panies to provide patients with a written notice explaining
a denial of a request [71].
Policy reforms such as the CURE Act Provisions could
provide patients with critical information to better assess
the utility of social media engagement based upon the
presence/absence and specific terms of a sponsor’s com-
passionate use/expanded access policies. The availability
of such information might preclude the need for individ-
uals to pursue direct advocacy that is unstructured,
time-intensive, and of questionable impact. Specifically,
the current lack of commitment by manufacturers to
proactively create expanded access policies or EAPs is a
significant barrier to patient education and treatment ac-
cess. Further, although a search for the term “expanded ac-
cess” on the National Institutes of Health (NIH) website
ClinicalTrials.gov yielded more than 300 results (including
active, closed, and finished studies) of expanded access
programs and protocols, navigating these results can be
unwieldy for patients and clinicians, and many
pharmaceutical firms do not actively publicize their EAPs.
The CURE Act Provisions were designed to specifically
address this limitation by making disclosure of expanded
access policies a condition of FDA investigational drug ap-
proval. By requiring disclosure as a condition for an IND,
the provisions could act as a catalyst for robust ex-
panded access policy creation, disclosure, and could
also lead to some needed industry standardization in
response to the growing patchwork of state “right-to-
try” laws.
The original CURE Act also required the Secretary of
Health and Human Services to establish an Expanded
Access Task Force to “explore mechanisms for improving
the access of individual patients have to investigational
drugs …” [71]. Specifically, the duties of this task force
would include exploring possible incentives for firms to
approve expanded access requests and evaluating ways to
streamline and standardize processes of submitting re-
quests by patients/clinicians. Revisiting the creation of
such a task force is worth merit as lack of financial incen-
tives appears to be a significant barrier to expanded access
approval by sponsors [18, 35, 47]. Designing financial in-
centives could be modeled based upon existing incentives
available under the Orphan Drug Act of 1983 (ODA), if
not already available for cancers related to rare or orphan
diseases [51]. This could include providing tax credits for
clinical trial costs associated with only intermediate-
sized expanded access INDs or protocols, to encourage
consolidation of expanded access requests, collection of
potential data on adverse events, and streamline approval
processes for manufacturers. In all cases, any form of fi-
nancial incentives associated with expanded access pro-
grams should be appropriately structured to: 1) target
smaller/mid-sized firms that lack resources to develop
EAPs; 2) prioritize expanded access drug candidates with
high potential to meet the needs of an underserved popu-
lation without any viable treatment options; 3) balance fi-
nancial incentives with the currently poorly regulated
price of access to experimental treatment for patients; and
4) prioritize expanded access when responding to serious
public health emergencies (e.g. the 2013 MenB outbreak,
2014 Ebola outbreak, combating tuberculosis and anti-
microbial resistance, and use for opioid overdose interven-
tion) [18, 20, 46, 72–74].
Finally, efforts should be made to pragmatically sim-
plify the process for patients to search for and submit
expanded access requests to EAPs and the FDA. This
could include the development of a centralized database
that houses all expanded access policies and links directly
to pharmaceutical manufacturer/sponsor EAPs, as man-
dated to be disclosed under the CURE Act Provisions. The
database could also incorporate data already available
from ClinicalTrials.gov linking to existing expanded access
programs and protocols, which patients could then
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directly access if qualified. Other patient advocacy
stakeholders (such as the American Cancer Society,
which operates a free and confidential Clinical Trials
Matching Service) could then use these resources to pro-
vide services to help patients and their clinicians match
EAPs and expanded access programs/protocols that are
appropriate for each individual’s unique medical and per-
sonal circumstances. Manufacturers and industry trade
groups, such as the Biotechnology Industry Organization
and the Pharmaceutical Research and Manufacturers of
America that have expressed commitment to improving
expanded access pathways, should also aid in the creation
of this information source in partnership with patient ad-
vocacy groups and the FDA [56].
Conclusions
Regardless of the medium, use of online petitions and
social media platforms by terminally ill patients in the
hope of gaining access to experimental treatment is sure
to continue in a growing “digital” and “social” health
landscape. Importantly, this form of digital patient advocacy
appears to be a symptom of current policy fragmentation
between the FDA, individual states, industry, and patient
advocacy groups, as well as the absence of reliable informa-
tion sources needed for patients when assessing whether
expanded access pathways are viable options in the face of
often serious and terminal diseases. Hence, lessons learned
from the case studies reviewed and the policy environment
examined provides a compelling reason to explore pro-
active reform of current expanded access policies. This
should include taking advantage of heightened attention to
the issue headlined by the CURE Act Provisions contained
in the 21st Century Cures Act, though the legislation faces
its own uncertain future as the U.S. Senate takes it up in
2016. While expanded access may not be the best option
for the vast majority of individuals, comprehensive,
accurate, and easily accessible information detailing
expanded access options will go a long way to help termin-
ally ill patients and their families make informed choices on
the utility of pursuing an online petition or social media
campaign in the hope of gaining access to experimental
drugs.
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